Two Li-Fraumeni syndrome families with novel germline p53 mutations: loss of the wild-type p53 allele in only 50% of tumours
1998

Germline p53 mutations in Li-Fraumeni syndrome families

Sample size: 6 publication Evidence: moderate

Author Information

Author(s): Z Sedlacek, R Kodet, V Krizl, E Seemanova, P Vodvarka, P Wilgenbus, J Mares, A Poustka, P Goetz

Primary Institution: Institute of Biology and Medical Genetics, Second Medical School, Charles University, Prague, Czech Republic

Hypothesis

Do novel germline p53 mutations affect the loss of the wild-type p53 allele in Li-Fraumeni syndrome families?

Conclusion

The study identified two novel germline p53 mutations in Li-Fraumeni syndrome families, with varying patterns of loss of heterozygosity in associated tumors.

Supporting Evidence

  • Two novel germline mutations in the p53 gene were identified in both families studied.
  • Three out of six tumors examined showed loss of heterozygosity and contained only the mutant p53 allele.
  • Immunohistochemistry confirmed p53 protein accumulation in tumors with loss of heterozygosity.

Takeaway

Some families with a rare cancer syndrome have changes in a gene that can lead to cancer, but not all tumors lose the normal version of that gene.

Methodology

Direct sequencing of p53 gene exons and analysis of tumors for loss of heterozygosity and p53 protein accumulation.

Limitations

The study is limited by the small sample size and the need for further research to understand genotype-phenotype correlations.

Participant Demographics

Two families with Li-Fraumeni syndrome, including children with early-onset tumors.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication